AR034023A1 - Compuestos benzimidazoles para modular la ige e inhibir la proliferacion celular - Google Patents

Compuestos benzimidazoles para modular la ige e inhibir la proliferacion celular

Info

Publication number
AR034023A1
AR034023A1 ARP020100869A ARP020100869A AR034023A1 AR 034023 A1 AR034023 A1 AR 034023A1 AR P020100869 A ARP020100869 A AR P020100869A AR P020100869 A ARP020100869 A AR P020100869A AR 034023 A1 AR034023 A1 AR 034023A1
Authority
AR
Argentina
Prior art keywords
cell proliferation
inhibit cell
modulate ige
ige
benzimidazol
Prior art date
Application number
ARP020100869A
Other languages
English (en)
Spanish (es)
Inventor
Mark Richards
Michael Major
Jagadish Sircar
Original Assignee
Avanir Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avanir Pharmaceuticals filed Critical Avanir Pharmaceuticals
Publication of AR034023A1 publication Critical patent/AR034023A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP020100869A 2001-03-12 2002-03-11 Compuestos benzimidazoles para modular la ige e inhibir la proliferacion celular AR034023A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27526001P 2001-03-12 2001-03-12

Publications (1)

Publication Number Publication Date
AR034023A1 true AR034023A1 (es) 2004-01-21

Family

ID=34115140

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020100869A AR034023A1 (es) 2001-03-12 2002-03-11 Compuestos benzimidazoles para modular la ige e inhibir la proliferacion celular

Country Status (20)

Country Link
US (2) US7282518B2 (enExample)
EP (1) EP1368028B1 (enExample)
JP (1) JP2004528304A (enExample)
CN (1) CN1496257A (enExample)
AR (1) AR034023A1 (enExample)
AT (1) ATE369853T1 (enExample)
BR (1) BR0208010A (enExample)
CA (1) CA2441177A1 (enExample)
CZ (1) CZ20032691A3 (enExample)
DE (1) DE60221804T2 (enExample)
DK (1) DK1368028T3 (enExample)
ES (1) ES2291455T3 (enExample)
HU (1) HUP0303460A3 (enExample)
MX (1) MXJL03000027A (enExample)
NZ (1) NZ528835A (enExample)
PL (1) PL364230A1 (enExample)
PT (1) PT1368028E (enExample)
RU (1) RU2003127367A (enExample)
WO (1) WO2002072090A1 (enExample)
ZA (1) ZA200307916B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6919366B2 (en) * 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
JP2004528304A (ja) * 2001-03-12 2004-09-16 アバニール・ファーマシューティカルズ IgEを調節し、細胞増殖を阻害するためのベンゾイミダゾール化合物
US8354397B2 (en) * 2001-07-27 2013-01-15 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
EP1388535A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated arylcycloalkylamines and their use as pharmaceuticals
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
AU2003270426A1 (en) * 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
US20050239844A1 (en) * 2002-11-02 2005-10-27 Kyung-Lim Lee Composition fo preventing secretion of immunoglobulin e-dependent histamine releasing factor
ATE363905T1 (de) * 2003-04-17 2007-06-15 Janssen Pharmaceutica Nv 2-phenyl-benzimidazol und 2-phenyl-imidazo-4,5)- pyridin-derivate als checkpoint-kinase-cds1 (chk2)-hemmer zur behandlung von krebs
AU2004263190A1 (en) * 2003-08-08 2005-02-17 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
US7485658B2 (en) * 2003-08-21 2009-02-03 Osi Pharmaceuticals, Inc. N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors
BRPI0413785A (pt) 2003-08-21 2006-11-07 Osi Pharm Inc composto, composição, e, método de tratamento de distúrbio hiperproliferativo
DE602005027739D1 (de) 2004-06-30 2011-06-09 Janssen Pharmaceutica Nv Arylsubstituiertes benzimidazol- und imidazopyridinether als wirkstoffe gegen krebs
CN101300251B (zh) * 2005-09-06 2011-08-03 史密丝克莱恩比彻姆公司 作为plk抑制剂的苯并咪唑噻吩化合物
JP2009001495A (ja) * 2005-10-13 2009-01-08 Taisho Pharmaceutical Co Ltd 2−アリール−ベンゾイミダゾール−5−カルボキサミド誘導体
ATE533485T1 (de) 2005-10-31 2011-12-15 Merck Sharp & Dohme Cetp-inhibitoren
AU2006311914C1 (en) * 2005-11-03 2013-10-24 Chembridge Corporation Heterocyclic compounds as tyrosine kinase modulators
GB0606774D0 (en) * 2006-04-03 2006-05-10 Novartis Ag Organic compounds
AR063311A1 (es) 2006-10-18 2009-01-21 Novartis Ag Compuestos organicos
WO2008128968A1 (en) * 2007-04-19 2008-10-30 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutamate receptor-5
WO2009043784A1 (en) 2007-10-04 2009-04-09 F. Hoffmann-La Roche Ag Cyclopropyl aryl amide derivatives and uses thereof
WO2009112445A1 (en) * 2008-03-10 2009-09-17 Novartis Ag Method of increasing cellular phosphatidyl choline by dgat1 inhibition
CN103288803B (zh) * 2013-05-17 2017-10-31 郎恒元 苯并咪唑酰胺类化合物及其制备方法和应用
CN104208701A (zh) * 2013-05-29 2014-12-17 天津金耀集团有限公司 含有抗真菌药物的复方吸入制剂
CN110234640B (zh) * 2016-09-20 2023-04-07 利昂贝拉尔中心 作为抗癌剂的苯并咪唑衍生物
EP3810117A4 (en) * 2018-06-01 2022-03-02 Merck Sharp & Dohme Corp. NEW [3.3.1] BICYCLO COMPOUNDS AS INDOLAMINE-2,3-DIOXYGENASE INHIBITORS

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3224512A1 (de) 1982-07-01 1984-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue imidazolderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel
US4510158A (en) 1984-03-05 1985-04-09 Sterling Drug Inc. 2-Phenylindole derivatives, their use as complement inhibitors
WO1986006739A1 (en) 1985-05-03 1986-11-20 The Foxboro Company Distillation cut point control
US4939133A (en) 1985-10-01 1990-07-03 Warner-Lambert Company N-substituted-2-hydroxy-α-oxo-benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade
LU86258A1 (fr) 1986-01-21 1987-09-03 Rech Dermatologiques C I R D S Composes benzamido aromatique,leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique
US5206257A (en) 1987-03-05 1993-04-27 May & Baker Limited Pesticidal method using 2-phenylimidazole derivatives
JP2630432B2 (ja) 1987-08-24 1997-07-16 コニカ株式会社 新規なシアンカプラーを含有するハロゲン化銀カラー写真感光材料
ES2058490T3 (es) 1988-02-02 1994-11-01 Schering Biotech Corp Metodo de reducir respuestas de inmunoglobulina e.
JP2700475B2 (ja) 1988-07-30 1998-01-21 コニカ株式会社 非線形光学材料および非線形光学素子
IT1232252B (it) 1989-02-22 1992-01-28 Rotta Research Lab Derivati della n fenil benzamide ad attivita' antiulcera ed antiallerica e procedimento per la loro preparazione
FR2643903A1 (fr) 1989-03-03 1990-09-07 Union Pharma Scient Appl Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux
EP0415886A3 (en) 1989-08-30 1991-10-23 Ciba-Geigy Ag Aza compounds
FR2658511B1 (fr) 1990-02-16 1992-06-19 Union Pharma Scient Appl Nouveaux derives de benzimidazole et d'azabenzimidazole, antagonistes des recepteurs au thromboxane; leurs procedes de preparation, compositions pharmaceutiques les contenant.
AU8225991A (en) 1990-07-31 1992-03-02 Teikoku Hormone Mfg. Co., Ltd. 2-phenylindole derivative
DK0469477T3 (da) 1990-08-02 1995-12-27 Hoffmann La Roche Antiallergisk kombination
US5656762A (en) 1990-12-28 1997-08-12 Neurogen Corporation 4-piperidino-and piperazinomethyl-2-phenylimidazole derivatives, dopamine receptor subtype specific ligands
JPH06263993A (ja) 1991-01-21 1994-09-20 Konica Corp アゾメチン系染料、インドアニリン系染料及びインドフェノール系染料の製造法
IE71647B1 (en) 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
EP0607373B1 (en) 1992-06-15 1997-03-19 Celltech Therapeutics Limited Trisubstituted phenyl derivatives as selective phosphodiesterase iv inhibitors
US5322847A (en) 1992-11-05 1994-06-21 Pfizer Inc. Azabenzimidazoles in the treatment of asthma, arthritis and related diseases
IL113472A0 (en) 1994-04-29 1995-07-31 Lilly Co Eli Non-peptidyl tachykinin receptor antogonists
US5643893A (en) 1994-06-22 1997-07-01 Macronex, Inc. N-substituted-(Dihydroxyboryl)alkyl purine, indole and pyrimidine derivatives, useful as inhibitors of inflammatory cytokines
DE4426625A1 (de) 1994-07-27 1996-03-14 Schering Ag 2-Phenylindole, Verfahren zu deren Herstellung, diese enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
US5496826A (en) 1994-09-02 1996-03-05 Bristol-Myers Squibb Company Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides
US5821258A (en) * 1994-12-27 1998-10-13 Mitsui Chemicals, Inc. Phenylbenzimidazole derivatives
DE19503160A1 (de) 1995-02-01 1996-08-08 Bayer Ag Verwendung von Phenylcyclohexylcarbonsäureamiden
IL123147A (en) 1995-08-02 2004-02-19 Univ Newcastle Ventures Ltd Benzamide imidazole - 4 carboxamide and their use
US6387938B1 (en) 1996-07-05 2002-05-14 Mochida Pharmaceutical Co., Ltd. Benzimidazole derivatives
TW467902B (en) 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
US6153631A (en) 1996-10-23 2000-11-28 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
JP2001510450A (ja) 1996-10-23 2001-07-31 ザイモジェネティクス,インコーポレイテッド 骨欠損状態を処置するための組成物および方法
CA2232467A1 (en) 1997-03-20 1998-09-20 Richard A. Glennon Imidazoles with serotonin receptor binding activity
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
CN1265665A (zh) 1997-06-10 2000-09-06 葛兰素集团有限公司 苯并咪唑衍生物
GB9718833D0 (en) 1997-09-04 1997-11-12 Merck Sharp & Dohme Therapeutic agents
ATE281834T1 (de) 1997-09-26 2004-11-15 Zentaris Gmbh Azabenzimidazol-verbindungen zur modulation der serin/threonin protein-kinase funktion
US6100282A (en) 1998-01-02 2000-08-08 Hoffman-La Roche Inc. Thiazole derivatives
US6303645B1 (en) 1998-05-22 2001-10-16 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
US6911462B2 (en) 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
US6271390B1 (en) 1998-05-22 2001-08-07 Avanir Pharmaceuticals Suppression of the IgE-dependent allergic response by benzimidazole analogs
US6919366B2 (en) 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
US6369091B1 (en) 1998-05-22 2002-04-09 Avanir Pharmaceuticals Benzimidazole analogs as down-regulators of IgE
JP2000095767A (ja) * 1998-09-28 2000-04-04 Takeda Chem Ind Ltd 性腺刺激ホルモン放出ホルモン拮抗剤
NZ510760A (en) 1998-10-23 2003-08-29 F Bicyclic nitrogen heterocycles
CN1331682A (zh) * 1998-11-03 2002-01-16 巴斯福股份公司 取代的2-苯基苯并咪唑类,其制备和用途
HRP20010451A2 (en) 1998-11-17 2003-04-30 Basf Ag 2-phenylbenzimidazoles and 2-phenylindoles, and production and use thereof
IL143303A0 (en) 1998-11-27 2002-04-21 Basf Ag Substituted benzimidazoles and their use as parp inhibitors
DE19918211A1 (de) 1999-04-22 2000-10-26 Basf Ag Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung
DE19920936A1 (de) 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
US6423734B1 (en) 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
DE19939463A1 (de) 1999-08-20 2001-02-22 Boehringer Ingelheim Pharma Aminocarbonyl-substituierte Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US6759425B2 (en) 1999-10-21 2004-07-06 Avanir Pharmaceuticals Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
US6242461B1 (en) 2000-01-25 2001-06-05 Pfizer Inc. Use of aryl substituted azabenzimidazoles in the treatment of HIV and AIDS related diseases
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
US6537994B2 (en) 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
JP2004528304A (ja) * 2001-03-12 2004-09-16 アバニール・ファーマシューティカルズ IgEを調節し、細胞増殖を阻害するためのベンゾイミダゾール化合物
MXPA03008205A (es) 2001-03-12 2004-01-29 Janssen Pharmaceutica Nv Procedimiento para la preparacion de compuestos de imidazol.
US6777442B2 (en) 2001-03-12 2004-08-17 Bayer Aktiengesellschaft Diphenyl derivatives
TW200304820A (en) 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
AU2003270426A1 (en) 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
RU2005134670A (ru) 2003-04-10 2006-06-10 Аванир Фармасьютикалс (Us) Производные имидазола для лечения аллергических и гиперпролиферативных нарушений
AU2004263190A1 (en) 2003-08-08 2005-02-17 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases

Also Published As

Publication number Publication date
EP1368028A1 (en) 2003-12-10
BR0208010A (pt) 2004-12-21
DE60221804D1 (de) 2007-09-27
DE60221804T2 (de) 2008-05-15
NZ528835A (en) 2005-05-27
ZA200307916B (en) 2004-09-03
CN1496257A (zh) 2004-05-12
JP2004528304A (ja) 2004-09-16
US20070202133A1 (en) 2007-08-30
ES2291455T3 (es) 2008-03-01
ATE369853T1 (de) 2007-09-15
US7282518B2 (en) 2007-10-16
MXJL03000027A (es) 2004-04-30
US20040214821A1 (en) 2004-10-28
RU2003127367A (ru) 2005-03-20
PT1368028E (pt) 2007-11-26
EP1368028B1 (en) 2007-08-15
CA2441177A1 (en) 2002-09-19
DK1368028T3 (da) 2007-12-27
PL364230A1 (en) 2004-12-13
WO2002072090A1 (en) 2002-09-19
CZ20032691A3 (en) 2004-04-14
HUP0303460A3 (en) 2004-07-28
HUP0303460A2 (hu) 2004-03-01

Similar Documents

Publication Publication Date Title
AR034023A1 (es) Compuestos benzimidazoles para modular la ige e inhibir la proliferacion celular
NO20005889D0 (no) Benzimidazolanaloger som ned-regulatorer av IgE
UY27732A1 (es) Uso de análogos del benzimidazol en el tratamiento de la proliferación celular.
PA8541601A1 (es) Derivados espirociclicos nuevos y su uso como inhibidores de fosfodiesterasa-7.
AR041252A1 (es) Compuestos de fenil - aza- benzimidazol para modular la ige e inhibir la proliferacion celular, uso en asma, alergia y cancer
PA8600601A1 (es) Ligandos de receptores de cannabinoides y sus usos
UY27729A1 (es) Inhibidores de quinasas.
ECSP088821A (es) Derivados de tioxantina y su uso como inhibidores de la mpo
AR023463A1 (es) Uso de compuestos de azetidinona
CU20070160A7 (es) Pirrolopirazoles, inhibidores potentes de quinasa
CL2007001665A1 (es) Anticuerpo o fragmento del mismo con actividad neutralizante de la proteina nr 10; agente que lo comprende; y su uso para prevenir o tratar una enfermedad inflamatoria.
GT200200028A (es) Compuestos de ppar
CR7716A (es) Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
ECSP066549A (es) Compuestos de pirazolilo e imidazolilo bicíclicos y usos de los mismos
PA8548401A1 (es) Agentes antibacterianos
UY26889A1 (es) Compuestos farmacéuticos
UY27418A1 (es) Formulaciones en combinación de derivados de propanol-amina sustituidos con arilo, junto con otras sustancias activas y su utilización
CR7977A (es) Anilidas de acido trifluorometil-tiofencarboxilico y su uso como fungicidas
BRPI0409097A (pt) derivados de imidazol para tratamento de distúrbios alérgicos e hiperproliferativos
HN2003000080A (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos y procedimientos para su uso
PA8555501A1 (es) Compuestos de benzimidazol sustituido y su uso para el tratamiento del cancer
MX9606503A (es) Inhibidores de pla2 y su uso para la inhibicion de la absorcion del colesterol interno.
CR10050A (es) Combinacion fungicida de productos activos
CR8177A (es) Compuestos de 3- arilpiridina arilcondensados y su empleo para combatir hongos nocivos

Legal Events

Date Code Title Description
FB Suspension of granting procedure